Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 2Gastrointestinal 2Dermatologic 2Sarcoma 1Other solid neoplasm 1NET 1Lymphoid 1Head & Neck 1Gynecologic 1Genitourinary 1Endocrine 1Breast 1

Conditions

Carcinoma, Renal Cell 40Kidney Neoplasms 30Melanoma 25Prostatic Neoplasms 24Breast Neoplasms 18Wilms Tumor 16Neoplasm Metastasis 16Ovarian Neoplasms 14Carcinoma, Non-Small-Cell Lung 12Testicular Neoplasms 11Multiple Myeloma 11Uterine Cervical Neoplasms 10Sarcoma 9Pancreatic Neoplasms 9Neuroblastoma 9Testicular Germ Cell Tumor 8Lymphoma, Follicular 8Lymphoma 8Lung Neoplasms 8Hodgkin Disease 8Carcinoma, Hepatocellular 8Triple Negative Breast Neoplasms 7Neoplasms, Plasma Cell 7Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Lymphoma, Large-Cell, Immunoblastic 7Lymphoma, Large B-Cell, Diffuse 7Leukemia, Myeloid, Acute 7Leukemia, Lymphocytic, Chronic, B-Cell 7

Interventions

pembrolizumab 3Nivolumab 3atezolizumab 2fludarabine 1epacadostat 1durvalumab 1avelumab 1aldesleukin 1Interleukin-2 1Docetaxel 1Cyclophosphamide 1Carboxylesterase 1ALT-803 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Microsatellite Instability × Cyclophosphamide × Genitourinary × Clear all
NCT03841110 2023-05-01

FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors

Fate Therapeutics

Phase 1 Completed
37 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidThoracic

Breast Neoplasms, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Lymphoma, Melanoma, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Microsatellite Instability, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡